Apelin-potential therapy for COVID-19?
J Mol Cell Cardiol
; 145: 84-87, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-602090
ABSTRACT
We believe that, in parallel to the attempts for direct blockade of the SARS-CoV-2 penetration into host cell and repurposing drugs, finding new therapeutic strategies for patients with lung injury or cardiovascular complications/coagulopathies associated with COVID-19 should be paid particular attention. Apelin or its receptor agonists are of great potential treatment for COVID-19 through suppressing angiotensin-converting enzyme (ACE) and angiotensin II (Ang-II) production, as well as, down-regulating angiotensin receptor 1 (AT1R) and ACE2 up-regulation. These drugs have potential to improve acute lung injury and cardiovascular/coagulopathy complications in COVID-19 which are associated with elevated Ang-II/Ang(1-7) ratio.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Angiotensin-Converting Enzyme Inhibitors
/
Coronavirus Infections
/
Peptidyl-Dipeptidase A
/
Angiotensin II Type 1 Receptor Blockers
/
Betacoronavirus
/
Apelin
/
Apelin Receptors
Limits:
Animals
/
Humans
Language:
English
Journal:
J Mol Cell Cardiol
Year:
2020
Document Type:
Article
Affiliation country:
J.yjmcc.2020.06.007
Similar
MEDLINE
...
LILACS
LIS